190 related articles for article (PubMed ID: 17595657)
1. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer.
Tam L; McGlynn LM; Traynor P; Mukherjee R; Bartlett JM; Edwards J
Br J Cancer; 2007 Aug; 97(3):378-83. PubMed ID: 17595657
[TBL] [Abstract][Full Text] [Related]
2. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.
Denley SM; Jamieson NB; McCall P; Oien KA; Morton JP; Carter CR; Edwards J; McKay CJ
J Gastrointest Surg; 2013 May; 17(5):887-98. PubMed ID: 23435739
[TBL] [Abstract][Full Text] [Related]
3. Nuclear expression of pSTAT3
Marginean FE; Hellsten R; Krzyzanowska A; Bjartell A
Pathol Res Pract; 2022 Apr; 232():153811. PubMed ID: 35259550
[TBL] [Abstract][Full Text] [Related]
4. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.
Berishaj M; Gao SP; Ahmed S; Leslie K; Al-Ahmadie H; Gerald WL; Bornmann W; Bromberg JF
Breast Cancer Res; 2007; 9(3):R32. PubMed ID: 17531096
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434.
Pastuschek J; Poetzsch J; Morales-Prieto DM; Schleußner E; Markert UR; Georgiev G
J Reprod Immunol; 2015 Apr; 108():48-55. PubMed ID: 25817464
[TBL] [Abstract][Full Text] [Related]
6. Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer.
Liu X; He Z; Li CH; Huang G; Ding C; Liu H
Pathol Oncol Res; 2012 Jan; 18(1):17-23. PubMed ID: 21681602
[TBL] [Abstract][Full Text] [Related]
7. Activation of the JAK-STAT signaling pathway in the rat basilar artery after subarachnoid hemorrhage.
Osuka K; Watanabe Y; Yamauchi K; Nakazawa A; Usuda N; Tokuda M; Yoshida J
Brain Res; 2006 Feb; 1072(1):1-7. PubMed ID: 16413512
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients.
McCall P; Gemmell LK; Mukherjee R; Bartlett JM; Edwards J
Br J Cancer; 2008 Mar; 98(6):1094-101. PubMed ID: 18349820
[TBL] [Abstract][Full Text] [Related]
9. Expression of tSTAT3, pSTAT3
Krzyzanowska A; Don-Doncow N; Marginean FE; Gaber A; Watson RW; Hellsten R; Bjartell A
Prostate; 2019 May; 79(7):784-797. PubMed ID: 30905090
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
11. Is PTEN loss associated with clinical outcome measures in human prostate cancer?
McCall P; Witton CJ; Grimsley S; Nielsen KV; Edwards J
Br J Cancer; 2008 Oct; 99(8):1296-301. PubMed ID: 18854827
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma.
Campbell CL; Jiang Z; Savarese DM; Savarese TM
Am J Pathol; 2001 Jan; 158(1):25-32. PubMed ID: 11141475
[TBL] [Abstract][Full Text] [Related]
13. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells.
Agarwal C; Tyagi A; Kaur M; Agarwal R
Carcinogenesis; 2007 Jul; 28(7):1463-70. PubMed ID: 17341659
[TBL] [Abstract][Full Text] [Related]
14. ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer.
Gustavsson H; Wang W; Jennbacken K; Welén K; Damber JE
BJU Int; 2009 Dec; 104(11):1786-90. PubMed ID: 19522863
[TBL] [Abstract][Full Text] [Related]
15. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
[TBL] [Abstract][Full Text] [Related]
16. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.
Isomäki P; Junttila I; Vidqvist KL; Korpela M; Silvennoinen O
Rheumatology (Oxford); 2015 Jun; 54(6):1103-13. PubMed ID: 25406356
[TBL] [Abstract][Full Text] [Related]
17. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
Sanford DC; DeWille JW
Prostate; 2005 May; 63(2):143-54. PubMed ID: 15486993
[TBL] [Abstract][Full Text] [Related]
18. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells.
Kroon P; Berry PA; Stower MJ; Rodrigues G; Mann VM; Simms M; Bhasin D; Chettiar S; Li C; Li PK; Maitland NJ; Collins AT
Cancer Res; 2013 Aug; 73(16):5288-98. PubMed ID: 23824741
[TBL] [Abstract][Full Text] [Related]
19. The interleukin-6/Janus kinase/STAT3 pathway in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the lacrimal gland.
Andreasen S; Heegaard S; Grauslund M; Homøe P
Acta Ophthalmol; 2016 Dec; 94(8):798-804. PubMed ID: 27286739
[TBL] [Abstract][Full Text] [Related]
20. STAT1 and STAT3 phosphorylation by porins are independent of JAKs but are dependent on MAPK pathway and plays a role in U937 cells production of interleukin-6.
Galdiero M; Vitiello M; D'Isanto M; Raieta K; Galdiero E
Cytokine; 2006 Dec; 36(5-6):218-28. PubMed ID: 17258468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
